AGPAT4 and neoplasm: As shown in Figure 7, 17 pLCGs were used to obtain multi-gene risk-scores in all cohorts, all of which had different expressions between tumor and non-tumor tissues (Figure 7A); 11 pLCGs were used to determine risk-scores in the luminal cohort, all of which had different expressions between tumor and non-tumor tissues (Figure 7D); 6 pLCGs were used to calculate risk-scores in the TNBC cohort, and AGPAT4, CRKL, NDP, PRRG1, and PYCR3 all had different expression between tumor and non-tumor tissues (Figure 7G).